UK Lung Cancer Patients Get Early Access To AZ's Osimertinib
This article was originally published in Scrip
Executive Summary
AstraZeneca UK Ltd's lung cancer drug osimertinib has become the latest product to gain a scientific opinion from the Medicines and Healthcare products Regulatory Agency (MHRA) under the Early Access to Medicines Scheme (EAMS), meaning it can now be made available to UK patients while it awaits European marketing approval.